Investigations reveal targeting IRF3 alleviates corneal inflammation, suggesting a new treatment approach.
IRF3 is a pivotal regulator of innate immune-driven stromal inflammation and opacity. Both genetic and pharmacologic inhibition of IRF3 attenuated cytokine and myeloid responses, suggesting that targeting IRF3, potentially via piceatannol (PIC), offers a therapeutic strategy for preserving corneal transparency.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: